$266 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 63.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $11,623,000 | +21.3% | 123,218 | +2.9% | 4.37% | +5.7% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $7,486,000 | -4.0% | 636,013 | +11.4% | 2.81% | -16.3% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $6,838,000 | +30.9% | 59,380 | +33.8% | 2.57% | +14.0% |
| GLPG | Buy | GALAPAGOS NVspon adr | $6,770,000 | +15.9% | 52,509 | +5.8% | 2.54% | +1.0% |
| ZGNX | Buy | ZOGENIX INC | $6,726,000 | -5.8% | 140,764 | +8.5% | 2.53% | -17.9% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $6,071,000 | -15.8% | 205,440 | +35.4% | 2.28% | -26.6% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $5,676,000 | -23.3% | 217,554 | +14.2% | 2.13% | -33.2% |
| ARQL | Buy | ARQULE INC | $5,480,000 | +206.7% | 497,762 | +33.4% | 2.06% | +167.2% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $5,455,000 | +12.6% | 64,608 | +17.5% | 2.05% | -1.9% |
| DXCM | Buy | DEXCOM INC | $5,445,000 | +41.4% | 36,338 | +12.4% | 2.05% | +23.2% |
| CYTK | Buy | CYTOKINETICS INC | $5,368,000 | +65.8% | 477,196 | +19.2% | 2.02% | +44.5% |
| CARA | Buy | CARA THERAPEUTICS INC | $4,408,000 | +56.4% | 205,011 | +42.8% | 1.66% | +36.3% |
| BHVN | Buy | BIOHAVEN PHARMACEUTICALS HOLD | $4,160,000 | +1.0% | 95,000 | +18.8% | 1.56% | -12.0% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $4,020,000 | -31.4% | 830,538 | +16.1% | 1.51% | -40.2% |
| LMNX | Buy | LUMINEX CORP | $4,006,000 | +25.8% | 194,091 | +40.2% | 1.51% | +9.6% |
| ELOX | New | ELOXX PHARMACEUTICALS INC | $3,739,000 | – | 375,000 | +100.0% | 1.40% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $2,879,000 | – | 734,422 | +100.0% | 1.08% | – |
| CRTX | New | CORTEXYME INC | $2,780,000 | – | 65,400 | +100.0% | 1.04% | – |
| PHAS | Buy | PHASEBIO PHARMACEUTICALS INC | $2,624,000 | +280.8% | 200,013 | +175.9% | 0.99% | +232.0% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $2,506,000 | -32.3% | 349,996 | +25.5% | 0.94% | -41.0% |
| TBIO | New | TRANSLATE BIO INC | $2,252,000 | – | 178,306 | +100.0% | 0.85% | – |
| BEAT | Buy | BIOTELEMETRY INC | $2,181,000 | +0.1% | 45,300 | +30.2% | 0.82% | -12.8% |
| EPZM | New | EPIZYME INC | $2,178,000 | – | 173,536 | +100.0% | 0.82% | – |
| ARAY | New | ACCURAY INC | $2,029,000 | – | 524,300 | +100.0% | 0.76% | – |
| ARDX | Buy | ARDELYX INC | $1,834,000 | -3.2% | 681,759 | +0.7% | 0.69% | -15.8% |
| KDMN | Buy | KADMON HOLDINGS INC | $1,826,000 | -8.7% | 886,177 | +17.0% | 0.69% | -20.4% |
| Buy | INTEC PHARMA LTD JERUSALEM | $1,805,000 | -35.5% | 415,989 | +9.0% | 0.68% | -43.7% | |
| VKTX | Buy | VIKING THERAPEUTICS INC | $1,736,000 | -2.5% | 209,200 | +16.7% | 0.65% | -15.0% |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $1,610,000 | – | 100,000 | +100.0% | 0.60% | – |
| INGN | Buy | INOGEN INC | $1,535,000 | +62.6% | 23,000 | +132.3% | 0.58% | +41.8% |
| NXTC | New | NEXTCURE INC | $1,440,000 | – | 96,100 | +100.0% | 0.54% | – |
| GMDA | New | GAMIDA CELL LTD | $1,397,000 | – | 275,000 | +100.0% | 0.52% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,219,000 | – | 60,031 | +100.0% | 0.46% | – |
| MORF | New | MORPHIC HOLDING INC | $1,189,000 | – | 60,000 | +100.0% | 0.45% | – |
| DERM | Buy | DERMIRA INC | $994,000 | +2.6% | 104,000 | +45.5% | 0.37% | -10.5% |
| PRVL | New | PREVAIL THERAPEUTICS INC | $990,000 | – | 75,000 | +100.0% | 0.37% | – |
| KURA | Buy | KURA ONCOLOGY INC | $930,000 | +53.5% | 47,242 | +29.2% | 0.35% | +34.1% |
| INSM | New | INSMED INC | $768,000 | – | 30,000 | +100.0% | 0.29% | – |
| OBSV | Buy | OBSEVA SA | $564,000 | +1.6% | 49,848 | +14.8% | 0.21% | -11.3% |
| GRTS | New | GRITSTONE ONCOLOGY INC | $557,000 | – | 50,000 | +100.0% | 0.21% | – |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $548,000 | -17.6% | 24,725 | +6.5% | 0.21% | -28.2% |
| KRTX | New | KARUNA THERAPEUTICS INC | $200,000 | – | 10,000 | +100.0% | 0.08% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $92,000 | – | 6,265 | +100.0% | 0.04% | – |
| ARCT | New | ARCTURUS THERAPEUTICS HLDG I | $23,000 | – | 2,400 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.